A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Blood

Volumn 118, Issue 14, 2011, Pages 3765-3776

  Fenaux, Pierre ^a   Giagounidis, Aristoteles ^b   Selleslag, Dominik ^c   Beyne Rauzy, Odile ^d   Mufti, Ghulam ^e   Mittelman, Moshe ^f   Muus, Petra ^g   Te Boekhorst, Peter ^h   Sanz, Guillermo ⁱ   Del Cañizo, Consuelo ^j   Guerci Bresler, Agnes ^k   Nilsson, Lars ^l   Platzbecker, Uwe ^m   Lübbert, Michael ⁿ   Quesnel, Bruno ^o   Cazzola, Mario ^p   Ganser, Arnold ^q   Bowen, David ^r   Schlegelberger, Brigitte ^q   Aul, Carlo ^b   Knight, Robert ^s   Francis, John ^s   Fu, Tommy ^s   Hellström Lindberg, Eva ^t   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b ST JOHANNES HOSPITAL   (Germany)

^c General Hospital St Jan   (Belgium)

^d CHU PURPAN   (France)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY OF PAVIA   (Italy)

^q HANNOVER MEDICAL SCHOOL   (Germany)

^r St James's Institute of Oncology   (United Kingdom)

^s CELGENE CORPORATION   (United States)

^t KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; PLACEBO;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; BLEEDING; CANCER RISK; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; INFECTION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 80053621748     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-330126     Document Type: Article

References (23)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
2. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q- anomaly. Cancer Genet Cytogenet. 1985;17(3):189-255. (Pubitemid 15051184)
3. Kelaidi C, Park S, Brechignac S, et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era: the GFM experience with EPO and thalidomide. Leuk Res. 2008;32(7):1049-1053.
4. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006;12(1):5-10. (Pubitemid 43166169)
5. Oliva EN, Dimitrov BD, Benedetto F, D'Angelo A, Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res. 2005;29(10):1217-1219. (Pubitemid 41169239)
6. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510. (Pubitemid 47315575)
7. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood. 2008;112(11):Abstract 640.
8. Eisenmann KM, Dykema KJ, Matheson SF, et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene. 2009;28(39):3429-3441.
9. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
10. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1):22-32.
11. Pellagatti A, Jädersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104(27):11406-11411. (Pubitemid 47175153)
12. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465. (Pubitemid 44511560)
13. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-3674.
14. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-425. (Pubitemid 44061337)
15. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199. (Pubitemid 12073508)
16. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 suppl 2):13-19. (Pubitemid 27319140)
17. Cella D, Eton D, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547-561. (Pubitemid 36120443)
18. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998;103(4):1070-1074.
19. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
20. List AF, Wride K, Dewald GW, et al. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion [abstract]. Leuk Res. 2007;31(suppl 1): S38. Abstract C028.
21. Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18(1):113-119. (Pubitemid 38159446)
22. Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011;25(1):110-120.
23. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395. (Pubitemid 351377805)